507 related articles for article (PubMed ID: 22161228)
41. Principles and current trends in the correlative evaluation of glioma with advanced MRI techniques and PET.
Tsiouris S; Bougias C; Fotopoulos A
Hell J Nucl Med; 2019; 22(3):206-219. PubMed ID: 31655848
[TBL] [Abstract][Full Text] [Related]
42. Applications of PET imaging of neurological tumors with radiolabeled amino acids.
Galldiks N; Langen KJ
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):70-82. PubMed ID: 25517079
[TBL] [Abstract][Full Text] [Related]
43. Value of 11C-methionine PET in imaging brain tumours and metastases.
Glaudemans AW; Enting RH; Heesters MA; Dierckx RA; van Rheenen RW; Walenkamp AM; Slart RH
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):615-35. PubMed ID: 23232505
[TBL] [Abstract][Full Text] [Related]
44. Positron emission tomography of high-grade gliomas.
Frosina G
J Neurooncol; 2016 May; 127(3):415-25. PubMed ID: 26897013
[TBL] [Abstract][Full Text] [Related]
45. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas.
Dhermain FG; Hau P; Lanfermann H; Jacobs AH; van den Bent MJ
Lancet Neurol; 2010 Sep; 9(9):906-20. PubMed ID: 20705518
[TBL] [Abstract][Full Text] [Related]
46. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy.
Floeth FW; Pauleit D; Wittsack HJ; Langen KJ; Reifenberger G; Hamacher K; Messing-Jünger M; Zilles K; Weber F; Stummer W; Steiger HJ; Woebker G; Müller HW; Coenen H; Sabel M
J Neurosurg; 2005 Feb; 102(2):318-27. PubMed ID: 15739561
[TBL] [Abstract][Full Text] [Related]
47. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
[TBL] [Abstract][Full Text] [Related]
48. Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas.
Stockhammer F; Misch M; Horn P; Koch A; Fonyuy N; Plotkin M
Acta Neurochir (Wien); 2009 Nov; 151(11):1377-83. PubMed ID: 19639250
[TBL] [Abstract][Full Text] [Related]
49. Molecular imaging (PET) of brain tumors.
Basu S; Alavi A
Neuroimaging Clin N Am; 2009 Nov; 19(4):625-46. PubMed ID: 19959009
[TBL] [Abstract][Full Text] [Related]
50. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
51. Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study): A Diagnostic Study Protocol.
Verburg N; Pouwels PJ; Boellaard R; Barkhof F; Hoekstra OS; Reijneveld JC; Vandertop WP; Wesseling P; de Witt Hamer PC
Neurosurgery; 2016 Oct; 79(4):535-40. PubMed ID: 27479710
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of amino acid PET-guided surgery for supratentorial high-grade gliomas.
Heinzel A; Stock S; Langen KJ; Müller D
J Nucl Med; 2012 Apr; 53(4):552-8. PubMed ID: 22419752
[TBL] [Abstract][Full Text] [Related]
53. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
54. Contribution of nuclear medicine to the diagnosis and management of primary brain tumours.
Horowitz T; Tabouret E; Graillon T; Salgues B; Chinot O; Verger A; Guedj E
Rev Neurol (Paris); 2023 Jun; 179(5):394-404. PubMed ID: 36934021
[TBL] [Abstract][Full Text] [Related]
55. PET and SPECT in low-grade glioma.
Minn H
Eur J Radiol; 2005 Nov; 56(2):171-8. PubMed ID: 16233891
[TBL] [Abstract][Full Text] [Related]
56. Advantages and limitations of amino acid PET for tracking therapy response in glioma patients.
Langen KJ; Heinzel A; Lohmann P; Mottaghy FM; Galldiks N
Expert Rev Neurother; 2020 Feb; 20(2):137-146. PubMed ID: 31829748
[No Abstract] [Full Text] [Related]
57. PET and SPECT studies in children with hemispheric low-grade gliomas.
Juhász C; Bosnyák E
Childs Nerv Syst; 2016 Oct; 32(10):1823-32. PubMed ID: 27659825
[TBL] [Abstract][Full Text] [Related]
58. Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI.
Cicone F; Filss CP; Minniti G; Rossi-Espagnet C; Papa A; Scaringi C; Galldiks N; Bozzao A; Shah NJ; Scopinaro F; Langen KJ
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):905-15. PubMed ID: 25750084
[TBL] [Abstract][Full Text] [Related]
59. Advances in magnetic resonance imaging of brain tumours.
Rees J
Curr Opin Neurol; 2003 Dec; 16(6):643-50. PubMed ID: 14624071
[TBL] [Abstract][Full Text] [Related]
60. Imaging gliomas with positron emission tomography and single-photon emission computed tomography.
Bénard F; Romsa J; Hustinx R
Semin Nucl Med; 2003 Apr; 33(2):148-62. PubMed ID: 12756647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
